SA517381566B1 - مركبات ثنائية الحلقة مدمجة لعلاج مرض - Google Patents
مركبات ثنائية الحلقة مدمجة لعلاج مرضInfo
- Publication number
- SA517381566B1 SA517381566B1 SA517381566A SA517381566A SA517381566B1 SA 517381566 B1 SA517381566 B1 SA 517381566B1 SA 517381566 A SA517381566 A SA 517381566A SA 517381566 A SA517381566 A SA 517381566A SA 517381566 B1 SA517381566 B1 SA 517381566B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- disease
- treatment
- fused bicyclic
- fxr
- bicyclic compounds
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 4
- 125000002619 bicyclic group Chemical group 0.000 title abstract 2
- 102100038495 Bile acid receptor Human genes 0.000 abstract 4
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 230000003143 atherosclerotic effect Effects 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 206010008635 Cholestasis Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000007870 cholestasis Effects 0.000 abstract 1
- 231100000359 cholestasis Toxicity 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 208000006132 lipodystrophy Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083031P | 2014-11-21 | 2014-11-21 | |
| PCT/US2015/062017 WO2016081918A1 (en) | 2014-11-21 | 2015-11-20 | Fused bicyclic compounds for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA517381566B1 true SA517381566B1 (ar) | 2021-05-16 |
Family
ID=56014622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA517381566A SA517381566B1 (ar) | 2014-11-21 | 2017-05-20 | مركبات ثنائية الحلقة مدمجة لعلاج مرض |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US10233187B2 (https=) |
| EP (1) | EP3221321B1 (https=) |
| JP (3) | JP7224102B2 (https=) |
| KR (1) | KR20170117020A (https=) |
| CN (2) | CN111662297A (https=) |
| AU (2) | AU2015349687B2 (https=) |
| CA (1) | CA2968434A1 (https=) |
| CL (1) | CL2017001289A1 (https=) |
| CO (1) | CO2017005784A2 (https=) |
| ES (1) | ES2911293T3 (https=) |
| IL (1) | IL252309B (https=) |
| MX (1) | MX370480B (https=) |
| MY (1) | MY192927A (https=) |
| RU (1) | RU2706007C2 (https=) |
| SA (1) | SA517381566B1 (https=) |
| SG (2) | SG10202010386PA (https=) |
| WO (1) | WO2016081918A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| CR20170077A (es) | 2014-08-04 | 2017-06-26 | Nuevolution As | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias |
| CN111662297A (zh) * | 2014-11-21 | 2020-09-15 | 阿卡纳治疗学有限公司 | 用于治疗疾病的稠合双环化合物 |
| EP3715348A1 (en) * | 2015-03-26 | 2020-09-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| BR112018073460A2 (pt) * | 2016-05-25 | 2019-07-09 | Akarna Therapeutics Ltd | terapias combinadas usando moduladores do receptor farnesoide x (fxr) |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| SI4122464T1 (sl) | 2017-03-28 | 2024-07-31 | Gilead Sciences, Inc. | Terapevtske kombinacije za zdravljenje bolezni jeter |
| RU2019144064A (ru) * | 2017-06-02 | 2021-07-13 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения |
| PT3911647T (pt) | 2019-01-15 | 2024-03-04 | Gilead Sciences Inc | Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| CN111825653A (zh) | 2019-04-19 | 2020-10-27 | 安道麦马克西姆有限公司 | 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途 |
| EP4003349A1 (en) | 2019-07-23 | 2022-06-01 | Novartis AG | Combination treatment of liver diseases using fxr agonists |
| US20220265614A1 (en) | 2019-07-23 | 2022-08-25 | Novartis Ag | Treatment comprising fxr agonists |
| CA3153062A1 (en) | 2019-09-03 | 2021-03-11 | Novartis Ag | Treatment of liver disease or disorder comprising actrii receptor antagonists |
| JP2022548617A (ja) | 2019-09-19 | 2022-11-21 | ノバルティス アーゲー | Ｆｘｒアゴニストを含む処置 |
| JP2022550312A (ja) | 2019-09-30 | 2022-12-01 | ノバルティス アーゲー | Ｆｘｒアゴニストの使用を含む処置 |
| UY38994A (es) | 2019-12-20 | 2021-07-30 | Nuevolution As | Compuestos activos frente a receptores nucleares |
| MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| US20230060422A1 (en) | 2019-12-20 | 2023-03-02 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| AU2021245397A1 (en) | 2020-03-31 | 2022-10-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2021198956A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
| UY39391A (es) * | 2020-08-24 | 2022-03-31 | Adama Makhteshim Ltd | Proceso para la preparación de pirazoles sustituidos |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| US8466143B2 (en) * | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
| ES2319539T3 (es) | 2003-09-17 | 2009-05-08 | Janssen Pharmaceutica Nv | Compuestos heterociclicos condensados como moduladores del receptor de serotonina. |
| US20090137554A1 (en) * | 2007-10-22 | 2009-05-28 | Wyeth | 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
| US20090215748A1 (en) * | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
| CA2736880A1 (en) | 2008-09-26 | 2010-04-01 | Wyeth Llc | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors |
| US8252826B2 (en) | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
| CN111662297A (zh) * | 2014-11-21 | 2020-09-15 | 阿卡纳治疗学有限公司 | 用于治疗疾病的稠合双环化合物 |
| KR20190040140A (ko) * | 2016-05-25 | 2019-04-17 | 아카나 테라퓨틱스, 엘티디. | 질환의 치료를 위한 융합된 비시클릭 화합물 |
-
2015
- 2015-11-20 CN CN202010634386.7A patent/CN111662297A/zh active Pending
- 2015-11-20 KR KR1020177016606A patent/KR20170117020A/ko not_active Ceased
- 2015-11-20 SG SG10202010386PA patent/SG10202010386PA/en unknown
- 2015-11-20 SG SG11201703953WA patent/SG11201703953WA/en unknown
- 2015-11-20 EP EP15861717.5A patent/EP3221321B1/en not_active Not-in-force
- 2015-11-20 CA CA2968434A patent/CA2968434A1/en active Pending
- 2015-11-20 ES ES15861717T patent/ES2911293T3/es active Active
- 2015-11-20 AU AU2015349687A patent/AU2015349687B2/en not_active Ceased
- 2015-11-20 WO PCT/US2015/062017 patent/WO2016081918A1/en not_active Ceased
- 2015-11-20 CN CN201580073351.8A patent/CN107207513B/zh not_active Expired - Fee Related
- 2015-11-20 JP JP2017545870A patent/JP7224102B2/ja active Active
- 2015-11-20 MY MYPI2017701793A patent/MY192927A/en unknown
- 2015-11-20 RU RU2017121588A patent/RU2706007C2/ru active
- 2015-11-20 MX MX2017006694A patent/MX370480B/es active IP Right Grant
-
2017
- 2017-05-16 IL IL252309A patent/IL252309B/en active IP Right Grant
- 2017-05-19 CL CL2017001289A patent/CL2017001289A1/es unknown
- 2017-05-19 US US15/599,647 patent/US10233187B2/en active Active
- 2017-05-20 SA SA517381566A patent/SA517381566B1/ar unknown
- 2017-06-12 CO CONC2017/0005784A patent/CO2017005784A2/es unknown
-
2019
- 2019-03-15 US US16/354,879 patent/US20190308977A1/en not_active Abandoned
-
2020
- 2020-07-22 JP JP2020125592A patent/JP2021011482A/ja active Pending
- 2020-09-18 US US17/025,724 patent/US20210147426A1/en not_active Abandoned
- 2020-10-08 AU AU2020250270A patent/AU2020250270B2/en not_active Ceased
-
2022
- 2022-09-16 US US17/932,876 patent/US20230183247A1/en not_active Abandoned
- 2022-10-26 JP JP2022171339A patent/JP2023011731A/ja active Pending
-
2024
- 2024-06-27 US US18/757,057 patent/US20250171446A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA517381566B1 (ar) | مركبات ثنائية الحلقة مدمجة لعلاج مرض | |
| MX2016015182A (es) | Compuestos triciclicos antidiabeticos. | |
| MX2017007522A (es) | Compuestos moduladores del receptor x farnesoide (frx) (receptor nr1h4) novedosos. | |
| PH12015502621A1 (en) | Estrogen receptor modulator and uses thereof | |
| EA201791017A1 (ru) | Гидроксисодержащие соединения, модулирующие fxr (nr1h4) | |
| MX2021008334A (es) | Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco. | |
| IL248130A0 (en) | Isoindolinone compounds as gpr119 regulators in the treatment of diabetes, obesity, dyslipidemia and related diseases | |
| MX382408B (es) | Coagonistas de los receptores de glucagón y de glp-1. | |
| IL248129A0 (en) | Transfused Heterocyclics as Gpr119 Regulators for the Treatment of Diabetes, Obesity, Dyslipidemia, and Related Disorders | |
| IL248118A0 (en) | Converted inanone compounds as gpr119 regulators for the treatment of diabetes, obesity, dyslipidemia and related diseases | |
| IL248668B (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | |
| EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
| PH12016501483A1 (en) | P-substituted asymmetric ureas and medical uses thereof | |
| AU2015278731B2 (en) | Fused triterpene compounds and uses thereof | |
| EP3182986A4 (en) | Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan | |
| MX2018007925A (es) | Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo. | |
| IL248670A0 (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | |
| EP3203998A4 (en) | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes | |
| MX371343B (es) | Moduladores del receptor x hepatico (lxr). | |
| MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). | |
| EA201491939A1 (ru) | Модуляторы прогестероновых рецепторов для применения в профилактике или лечении болезней, опосредованных андрогенами | |
| HK1230188A1 (en) | Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| HK1230187A1 (en) | Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| PH12019500090A1 (en) | Insulin analogs | |
| HK1228909A1 (en) | Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |